S Larsson1, M Englund2, A Struglics3, L S Lohmander4. 1. Department of Orthopaedics, Clinical Sciences Lund, Lund University, Lund, Sweden. Electronic address: staffan.larsson@med.lu.se. 2. Department of Orthopaedics, Clinical Sciences Lund, Lund University, Lund, Sweden; Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, USA. Electronic address: martin.englund@med.lu.se. 3. Department of Orthopaedics, Clinical Sciences Lund, Lund University, Lund, Sweden. Electronic address: andre.struglics@med.lu.se. 4. Department of Orthopaedics, Clinical Sciences Lund, Lund University, Lund, Sweden; Research Unit for Musculoskeletal Function and Physiotherapy, University of Southern Denmark, Denmark; Department of Orthopaedics and Traumatology, University of Southern Denmark, Denmark. Electronic address: stefan.lohmander@med.lu.se.
Abstract
OBJECTIVE: To investigate whether change in concentrations over time of aggrecanase generated ARGS-aggrecan in synovial fluid (SF ARGS) associates with progression of radiographic knee osteoarthritis (OA) and patient-reported outcome in subjects with previous meniscectomy. METHODS: We studied 141 subjects at two time points after meniscectomy. Time point A was on average 18 years after meniscectomy, time point B was on average 7.5 years later; 74 subjects had SF available from both examinations. We measured SF ARGS by an electrochemiluminescence immunoassay, graded radiographic features of tibiofemoral or patellofemoral OA according to the Osteoarthritis Research Society International (OARSI) atlas, and scored patient-reported outcomes using the Knee Injury and Osteoarthritis Outcome Score (KOOS). Using logistic regression (adjusted for age, gender, body mass index, time between examinations, and SF ARGS at first examination) we assessed associations between change in SF ARGS between first and second examinations and progression of radiographic OA and KOOS. RESULTS: In subjects with decreasing SF ARGS between examinations, the likelihood of loss of joint space and worsening of KOOS pain between examinations was increased 6- and 4-fold respectively compared to those increasing in SF ARGS (odds ratio (OR) 5.72; 95% confidence interval (CI) 1.53-21.4 and 3.66; 1.01-13.2, respectively). No significant associations were seen between decreasing SF ARGS and progression of osteophytes (OR 0.88; 0.28-2.78), or for patient-reported outcomes other than KOOS pain. CONCLUSION: Having decreasing levels of SF ARGS over time was associated with an increased risk of loss of joint space and pain worsening, but showed no association with other patient-reported outcomes or osteophyte progression.
OBJECTIVE: To investigate whether change in concentrations over time of aggrecanase generated ARGS-aggrecan in synovial fluid (SF ARGS) associates with progression of radiographic knee osteoarthritis (OA) and patient-reported outcome in subjects with previous meniscectomy. METHODS: We studied 141 subjects at two time points after meniscectomy. Time point A was on average 18 years after meniscectomy, time point B was on average 7.5 years later; 74 subjects had SF available from both examinations. We measured SF ARGS by an electrochemiluminescence immunoassay, graded radiographic features of tibiofemoral or patellofemoral OA according to the Osteoarthritis Research Society International (OARSI) atlas, and scored patient-reported outcomes using the Knee Injury and Osteoarthritis Outcome Score (KOOS). Using logistic regression (adjusted for age, gender, body mass index, time between examinations, and SF ARGS at first examination) we assessed associations between change in SF ARGS between first and second examinations and progression of radiographic OA and KOOS. RESULTS: In subjects with decreasing SF ARGS between examinations, the likelihood of loss of joint space and worsening of KOOS pain between examinations was increased 6- and 4-fold respectively compared to those increasing in SF ARGS (odds ratio (OR) 5.72; 95% confidence interval (CI) 1.53-21.4 and 3.66; 1.01-13.2, respectively). No significant associations were seen between decreasing SF ARGS and progression of osteophytes (OR 0.88; 0.28-2.78), or for patient-reported outcomes other than KOOS pain. CONCLUSION: Having decreasing levels of SF ARGS over time was associated with an increased risk of loss of joint space and pain worsening, but showed no association with other patient-reported outcomes or osteophyte progression.
Authors: Hope C Davis; Jeffery T Spang; Richard F Loeser; Staffan Larsson; Veronica Ulici; J Troy Blackburn; R Alexander Creighton; Ganesh M Kamath; Joanne M Jordan; Stephen W Marshall; Brian Pietrosimone Journal: Knee Date: 2018-03-07 Impact factor: 2.199
Authors: D Wasserstein; L J Huston; S Nwosu; C C Kaeding; R D Parker; R W Wright; J T Andrish; R G Marx; A Amendola; B R Wolf; E C McCarty; M Wolcott; W R Dunn; K P Spindler Journal: Osteoarthritis Cartilage Date: 2015-06-11 Impact factor: 6.576
Authors: Timothy W Tourville; Matthew E Poynter; Michael J DeSarno; André Struglics; Bruce D Beynnon Journal: J Orthop Res Date: 2015-07-17 Impact factor: 3.494
Authors: Scott M Wasilko; Timothy W Tourville; Michael J DeSarno; James R Slauterbeck; Robert J Johnson; André Struglics; Bruce D Beynnon Journal: J Orthop Res Date: 2015-11-25 Impact factor: 3.494
Authors: M Lotz; J Martel-Pelletier; C Christiansen; M-L Brandi; O Bruyère; R Chapurlat; J Collette; C Cooper; G Giacovelli; J A Kanis; M A Karsdal; V Kraus; W F Lems; I Meulenbelt; J-P Pelletier; J-P Raynauld; S Reiter-Niesert; R Rizzoli; L J Sandell; W E Van Spil; J-Y Reginster Journal: Postgrad Med J Date: 2014-03 Impact factor: 2.401
Authors: M Lotz; J Martel-Pelletier; C Christiansen; M-L Brandi; O Bruyère; R Chapurlat; J Collette; C Cooper; G Giacovelli; J A Kanis; M A Karsdal; V Kraus; W F Lems; I Meulenbelt; J-P Pelletier; J-P Raynauld; S Reiter-Niesert; R Rizzoli; L J Sandell; W E Van Spil; J-Y Reginster Journal: Ann Rheum Dis Date: 2013-07-29 Impact factor: 19.103